Results 201 to 210 of about 3,580,419 (303)
Systematic characterization of the liver‐resident microbiota in advanced metabolic dysfunction‐associated steatotic liver disease (MASLD) reveals a consistent depletion of Bacteroides uniformis (B. uniformis) in both hepatic and gut microbial communities. Oral gavage of B.
Haiyang Liu +4 more
wiley +1 more source
Capivasertib for locally advanced or metastatic breast cancer. [PDF]
europepmc +1 more source
In glioblastoma, M2‐polarized macrophages secrete IL‐6, which activates STAT3 signaling in tumor cells to upregulate CTSB. Tumor‐derived CTSB binds the C‐terminus of macrophage S100A10, reinforcing M2 polarization and further IL‐6 secretion, thereby establishing a feedforward IL‐6/STAT3/CTSB/S100A10 loop. This cascade drives tumor growth, invasion, and
Hao Zhang +11 more
wiley +1 more source
Fast-Food Component-Induced Epigenetic Modifications Modulate Immunotherapy in Metastatic Breast Cancer. [PDF]
Mukherjee A +4 more
europepmc +1 more source
Schematic representation of ultrasound‐mediated ICG/siCD24@MSN‐LCD from nanostructure to synergistic sono‐gene therapy. This nanoplatform targets ASGPR via the LCD shell, which dissociates to release loaded ICG and siCD24. The core mechanism involves ultrasound‐guided sonodynamic therapy by ICG and CD24 knockdown by siCD24, both activating the p53 axis
Yading Zhao +11 more
wiley +1 more source
Ribociclib and Palbociclib Are Safe and Effective for Treating Metastatic Breast Cancer: A Retrospective Study. [PDF]
Chou CW +6 more
europepmc +1 more source
Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier +16 more
wiley +1 more source
Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer - from feasibility to precision practice. [PDF]
Tan Y, Cheng B, He K, Xie X.
europepmc +1 more source
VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu +13 more
wiley +1 more source
On-Treatment NLR Dynamics During CDK4/6 Inhibition Are Associated with Overall Survival in Metastatic Breast Cancer. [PDF]
Sharaf B +8 more
europepmc +1 more source

